• Odyssey Therapeutics posted a net loss of $38.3 million in Q1 2026, roughly in line with the $38.4 million loss a year earlier.
• R&D expense fell 16.75% to $32.3 million, while G&A expense dipped 7.5% to $7.4 million.
• Cash, cash equivalents and marketable securities totaled $175.7 million at March 31; pro-forma cash rose to $464.4 million after IPO proceeds.
• The company expects its cash runway to extend into the second half of 2028.
• OD-001 Phase 2a ulcerative colitis data showed 27% clinical remission and 61% clinical response; Phase 2b and combo studies targeted for H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odyssey Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606171615PRIMZONEFULLFEED9748810) on June 17, 2026, and is solely responsible for the information contained therein.